Biostatistics & Population Health

Disease prevention levels: primary, secondary, tertiary

Clinical Overview and When to Suspect Prevention Gaps

— Primordial: prevent the risk factor itself from developing (population-level policy: sugar taxes, clean air laws, school PE mandates, tobacco-free generations).

— Primary: prevent disease onset in at-risk but disease-free individuals (immunizations, statins for elevated ASCVD risk, HPV vaccination, seatbelt counseling, PrEP for HIV).

— Secondary: detect asymptomatic or early disease and intervene before clinical manifestation (screening mammography, colonoscopy, A1c in prediabetes, BP measurement, DEXA).

— Tertiary: reduce complications, disability, and recurrence in established disease (cardiac rehab post-MI, DM foot care, stroke secondary prevention with statin+antiplatelet, pulmonary rehab in COPD).

— New patient establishing care with no documented screening history.

— Chronic disease visit where vignette lists "last colonoscopy 12 years ago" or "never received Tdap."

— Post-event encounters (recent MI, stroke, fracture, COPD exacerbation) — the question is almost always tertiary prevention.

— Pre-conception, pre-operative, and transition-of-care visits.

Prevention framework is the backbone of ambulatory Step 3 practice — every well visit, chronic disease check, and pre-op encounter is an opportunity to classify and act on prevention levels.

Four-tier model (modern public health expansion of the classic three):

When to suspect a prevention gap on Step 3:

Step 3 management: Always ask what level of prevention does this intervention represent? before selecting the answer. The exam frequently lists two correct-sounding interventions; the right one matches the patient's current disease state.

Board pearl: A statin in a 55-year-old with LDL 160 and no ASCVD = primary; the same statin in that patient one year after an MI = secondary (cardiology nomenclature) but tertiary in classic preventive medicine framework. USMLE typically uses the public health definition — know both.

Presentation Patterns and Key History

— Age and sex: drive USPSTF screening grids (mammography 40–74, colorectal 45–75, AAA in male smokers 65–75, lung CT 50–80 with 20 pack-year history).

— Tobacco, alcohol, substance use: triggers counseling (5 A's), pharmacotherapy offer (varenicline, NRT), and altered screening intervals.

— Sexual history: determines HPV vaccination catch-up (through age 26, shared decision 27–45), HIV/STI screening cadence, PrEP eligibility, cervical cancer screening modality.

— Family history: BRCA referral (Ashkenazi, premenopausal breast/ovarian cancer in 1st-degree relative), early colon cancer (<50 in relative → colonoscopy at 40 or 10 years before index case), premature ASCVD (<55 M / <65 F).

— Occupational/environmental: asbestos, radon, silica, lead → targeted screening.

— Reproductive history: parity, breastfeeding, menopause age, gestational DM history (T2DM screening q3y lifelong).

The "presentation" of prevention is the clinical encounter itself — Step 3 tests whether you recognize the right intervention for the right life stage and risk profile.

High-yield history elements that change prevention recommendations:

Social determinants: insurance status, food security, housing, transportation — all affect ability to complete preventive care and frequently appear in Step 3 vignettes as the rate-limiting step.

Vaccination history is the most commonly missed history element on Step 3 — always reconcile: Tdap q10y, influenza annually, COVID per current schedule, zoster (RZV) at 50, pneumococcal at 65 (or earlier with comorbidity), HPV through 26.

Key distinction: Counseling someone with no disease to wear a seatbelt = primary. Counseling a post-stroke patient on medication adherence = tertiary. The behavior may be identical; the prevention level depends on whether disease is already present.

Board pearl: When a vignette opens "a 52-year-old establishes care," your reflex should be a full USPSTF inventory — that is the question being asked.

Physical Exam Findings (and Risk Assessment when relevant)

— BP ≥130/80 repeated → lifestyle + pharmacotherapy per ACC/AHA; screen all adults ≥18.

— BMI ≥25 → intensive behavioral counseling (USPSTF Grade B); BMI ≥30 → offer pharmacotherapy/bariatric referral.

— Waist circumference >102 cm men / >88 cm women → metabolic syndrome workup.

— ASCVD Pooled Cohort Equation (age 40–75): ≥7.5% 10-yr risk → statin discussion; ≥20% → high-intensity statin.

— FRAX for osteoporosis: 10-yr hip fracture ≥3% or major osteoporotic ≥20% → treat.

— PHQ-2/PHQ-9 depression screening (USPSTF Grade B all adults).

— AUDIT-C for unhealthy alcohol use; DAST-10 for drug use.

— GAD-7 anxiety screening (USPSTF Grade B adults <65).

— Skin exam in high-risk patients (fair skin, family hx melanoma, immunosuppressed).

— Diabetic foot exam annually with monofilament — tertiary prevention of amputation.

— Oral exam for tobacco/alcohol users — tertiary prevention of metastatic disease.

— Fundoscopy or referral for annual dilated eye exam in DM — tertiary prevention of blindness.

The "exam" in prevention is structured risk assessment plus targeted screening maneuvers — Step 3 expects you to integrate vitals, anthropometrics, and validated tools.

Vital sign–driven prevention triggers:

Validated risk tools to deploy at the visit:

Targeted physical exam elements with screening value:

Step 3 management: When the vignette gives you a BP, BMI, and A1c, you are being asked to calculate layered risk and choose the highest-yield intervention. Tobacco cessation outranks almost everything except acute findings.

Board pearl: USPSTF does not recommend routine carotid bruit auscultation or whole-body skin exam in asymptomatic adults — both are Grade D (do not screen). Listing them as "preventive" on Step 3 is a distractor.

Diagnostic Workup — Core USPSTF Screening Grid

— Cervical: 21–29 cytology q3y; 30–65 cytology q3y OR HPV q5y OR co-test q5y; stop at 65 with adequate prior screening.

— Breast: biennial mammography 40–74 (2024 update lowered start age from 50).

— Colorectal: start at 45, continue to 75; options include colonoscopy q10y, FIT annually, FIT-DNA q1–3y, CT colonography q5y. 76–85 individualized.

— Lung: annual low-dose CT 50–80 with ≥20 pack-year history, currently smoking or quit within 15 years.

— Prostate: shared decision 55–69 (Grade C); do not screen ≥70.

— BP: all adults ≥18, annually if normal, more often if elevated.

— Lipids: statin for primary prevention 40–75 with ≥1 risk factor and ASCVD ≥10%.

— Diabetes/prediabetes: screen 35–70 if overweight/obese, q3y.

— AAA ultrasound: one-time, men 65–75 who ever smoked.

— Obesity: screen all; offer intensive behavioral intervention.

— HIV: one-time 15–65; more often if at risk.

— HCV: one-time all adults 18–79.

— HBV: all adults at least once.

— Syphilis, gonorrhea, chlamydia: risk-based; chlamydia/gonorrhea annually in women <25.

— Latent TB: risk-based (immigrants, healthcare workers, immunocompromised).

Cancer screening (Grade A/B):

Cardiovascular/metabolic:

Infectious disease:

Mental health/behavioral: depression, anxiety, IPV (reproductive-age women), unhealthy alcohol/drug use — all Grade B.

Step 3 management: Memorize the age cutoffs — the exam loves boundary cases (a 66-year-old former smoker for AAA; a 75-year-old for colonoscopy continuation).

Board pearl: Grade D = recommend against (ovarian CA screening in average-risk women, PSA ≥70, vitamin D for fall prevention in community-dwelling adults, beta-carotene/vitamin E for CVD prevention). Picking these = wrong answer.

Diagnostic Workup — Advanced/Risk-Enhanced Screening

— Family history of CRC in 1st-degree relative <60 or ≥2 relatives any age: colonoscopy starting age 40 or 10 years before index case, q5y.

— Lynch syndrome: colonoscopy q1–2y starting 20–25; endometrial sampling annually from 30–35.

— FAP: sigmoidoscopy/colonoscopy starting age 10–15 annually.

— BRCA1/2 carriers: annual MRI + mammography starting 25–30; discuss risk-reducing salpingo-oophorectomy by 35–40.

— Type 1 DM: annual urine albumin/creatinine ratio and dilated eye exam starting 5 years post-diagnosis.

— Type 2 DM: same screens at diagnosis, then annually.

When to deviate from standard USPSTF intervals (Step 3 frequently tests these):

Risk-enhancing factors that lower statin threshold (ACC/AHA): family hx premature ASCVD, CKD, metabolic syndrome, chronic inflammatory disease, premature menopause, South Asian ancestry, persistently elevated triglycerides, LDL ≥160, hs-CRP ≥2, Lp(a) ≥50, ApoB ≥130, CAC score > 0 (especially ≥100 or ≥75th percentile).

CAC scoring: useful in borderline (5–7.5%) or intermediate (7.5–20%) 10-yr ASCVD risk to refine decision; CAC = 0 may allow withholding statin in low-risk patients <75.

Genetic counseling referral triggers: Ashkenazi Jewish ancestry + family hx breast/ovarian/pancreatic/prostate, multiple cancers in family, bilateral or male breast cancer, early-onset cancer (<50).

Pre-conception screening: rubella/varicella immunity, HIV, syphilis, Hep B, folic acid 400–800 mcg, Tay-Sachs (Ashkenazi), hemoglobinopathy screen (African, Mediterranean, SE Asian ancestry).

Key distinction: Screening (asymptomatic) vs diagnostic testing (symptomatic) vs surveillance (known disease, prevent recurrence). A colonoscopy in a patient with rectal bleeding is diagnostic, not screening — and not "secondary prevention" on a Step 3 vignette.

Board pearl: Genetic testing requires pre- and post-test counseling — failing to offer it before ordering BRCA testing is a tested ethics violation.

Risk Stratification — Choosing the Right Prevention Level

— Step 1: Does the patient have the disease in question?

→ No, never at risk = primordial.

→ No, but has risk factors = primary.

→ Asymptomatic but possibly present = secondary.

→ Yes, established = tertiary.

— Step 2: Match intervention to that level.

— Step 3: Confirm intervention has evidence (USPSTF Grade A/B, guideline-supported).

— HPV vaccine → primary (prevents infection that causes cancer).

— Pap/HPV co-test → secondary (detects dysplasia before invasive cancer).

— LEEP/cone for CIN3 → tertiary (treats established precancer to prevent invasion).

— Cervical cancer chemoradiation → quaternary in some frameworks, tertiary in classic three-tier.

— Folate fortification of grain → primordial.

— Folic acid 400 mcg in pregnancy → primary (prevents NTDs).

— Fetal ultrasound for NTD → secondary.

— Neonatal NTD surgical repair → tertiary.

Decision framework Step 3 expects:

Classic mappings to memorize:

Cardiac rehab post-MI = tertiary (prevents recurrence, restores function).

Aspirin 81 mg in known CAD = tertiary; aspirin for primary prevention = now generally not recommended (USPSTF 2022: do not initiate in adults ≥60; individualized 40–59 with ≥10% ASCVD risk and low bleeding risk).

Step 3 management: When two prevention answers exist, prioritize by (1) magnitude of benefit, (2) USPSTF grade, (3) patient preference. Tobacco cessation has the largest NNT advantage of any single intervention in primary care.

Board pearl: Quaternary prevention is an emerging concept = preventing overmedicalization and iatrogenic harm (e.g., deprescribing in elderly, avoiding low-value screening like PSA in 80-year-olds). Increasingly appears on Step 3 in geriatrics vignettes.

Pharmacotherapy — Prevention-Specific Drug Regimens

— Statins: moderate-intensity (atorvastatin 10–20, rosuvastatin 5–10) for ASCVD risk ≥7.5% age 40–75; high-intensity if ≥20%.

— Aspirin: not for routine primary prevention; individualized 40–59 with high ASCVD/low bleed risk.

— Metformin for prediabetes (A1c 5.7–6.4, BMI ≥35, age <60, prior GDM) — off-label but ADA-endorsed.

— PrEP: TDF/FTC or TAF/FTC daily, or long-acting cabotegravir IM q2mo, for HIV-negative high-risk individuals.

— Tamoxifen/raloxifene/aromatase inhibitors: chemoprevention for women with ≥3% 5-yr breast cancer risk (Gail model) and low bleed/thrombosis risk.

— Statin for newly detected dyslipidemia.

— Antihypertensive for stage 1–2 HTN detected on screening.

— Metformin for newly diagnosed T2DM.

— Bisphosphonate for screen-detected osteoporosis (T-score ≤−2.5).

— A: Aspirin + P2Y12 inhibitor (DAPT 12 mo), ACEi/ARB.

— B: Beta-blocker, BP control.

— C: Cholesterol (high-intensity statin, LDL goal <70, consider ezetimibe/PCSK9), Cigarette cessation.

— D: Diet, Diabetes control.

— E: Exercise, Education, cardiac rehab Enrollment.

Primary prevention pharmacotherapy:

Secondary prevention pharmacotherapy (after screen detects early disease):

Tertiary prevention "ABCDE" post-MI:

Post-stroke: antiplatelet (or anticoagulation if AFib), high-intensity statin, BP <130/80, A1c <7%.

COPD tertiary: LABA/LAMA ± ICS, pulmonary rehab, vaccinations, smoking cessation.

Step 3 management: When stem says "recently discharged after MI," your reflex order set is ASA + P2Y12 + statin high-intensity + beta-blocker + ACEi + cardiac rehab referral — missing any one is the wrong answer.

Board pearl: PCSK9 inhibitors and inclisiran are reserved for secondary prevention (or familial hypercholesterolemia) when max statin + ezetimibe fails to achieve LDL <70.

Procedures and Counseling Interventions

— Vaccinations (most cost-effective intervention in medicine): influenza annual; Tdap q10y; HPV 9-valent (ideally 11–12, catch-up to 26); zoster RZV 2-dose at ≥50; pneumococcal PCV20 or PCV15+PPSV23 at 65 (or earlier with chronic disease/immunocompromise); RSV one-time ≥60 shared decision, ≥75 routine; COVID per current schedule; Hep B all adults 19–59 (and ≥60 with risk factors).

— Risk-reducing surgery: prophylactic mastectomy or BSO in BRCA carriers; total colectomy in FAP.

— Polypectomy at screening colonoscopy — both diagnostic and preventive in one act.

— LEEP/cryotherapy for CIN2/3 detected on Pap.

— DCIS lumpectomy + radiation detected on screening mammogram.

— PCI/CABG after MI to prevent recurrent ischemia.

— ICD for EF ≤35% post-MI (≥40 days) — sudden death prevention.

— Carotid endarterectomy for symptomatic 70–99% stenosis post-TIA.

— Intensive behavioral counseling for unhealthy diet/physical activity in adults with CV risk factors.

— Tobacco cessation with 5 A's (Ask, Advise, Assess, Assist, Arrange) + pharmacotherapy (varenicline > combo NRT > bupropion).

— Alcohol brief intervention for unhealthy use.

— Fall prevention exercise in community-dwelling adults ≥65 with elevated fall risk.

— Healthy weight gain counseling in pregnancy.

Procedural primary prevention:

Procedural secondary prevention:

Procedural tertiary prevention:

Counseling interventions (USPSTF Grade B, often missed):

CCS pearl: On a CCS case for routine well-visit, the highest-yield orders are Counseling: tobacco cessation, Counseling: diet/exercise, plus indicated vaccines and screening labs — even when no abnormality is stated, these advance the clock and accumulate scoring.

Board pearl: Varenicline is first-line for tobacco cessation in most adults; no longer carries black box for neuropsychiatric effects (removed 2016 after EAGLES trial).

Special Populations — Elderly and Renal/Hepatic Impairment

— Stop cancer screening when life expectancy <10 years (mammography, colonoscopy, PSA, cervical).

— Cervical screening stops at 65 with adequate prior; colonoscopy 76–85 individualized; >85 do not screen.

— AAA screening one-time only 65–75 male ever-smokers; not repeated.

— Statins for primary prevention >75: shared decision; evidence weaker, frailty and polypharmacy matter.

— Aspirin: discontinue primary prevention in adults ≥60 (USPSTF 2022).

— Bisphosphonate "drug holiday" after 5 years oral (10 years if high risk) to reduce atypical fracture/ONJ.

— Adjust metformin by eGFR (avoid <30, reduce dose 30–45).

— Statins: rosuvastatin max 10 mg if CrCl <30.

— Bisphosphonates contraindicated when eGFR <30–35; use denosumab instead (no renal dose adjustment, but monitor for hypocalcemia).

— SGLT2 inhibitors retain cardiorenal benefit down to eGFR 20–25 (empagliflozin, dapagliflozin) — tertiary prevention in CKD/HF.

Geriatric prevention pivots from "add" to "deprescribe":

Falls (Grade B): annual fall risk screen ≥65; exercise/PT for elevated risk; vitamin D not recommended for fall prevention in community-dwelling adults (USPSTF Grade D, 2018 update).

Vaccinations in elderly: RZV (zoster) ≥50, RSV ≥75 routine, high-dose or adjuvanted influenza preferred ≥65, PCV20 at 65.

Renal impairment considerations:

Hepatic impairment: avoid statins in active liver disease/decompensated cirrhosis; can use in compensated NAFLD (often beneficial).

Step 3 management: A frail 82-year-old with dementia and 4-year life expectancy asking about a "routine colonoscopy" — correct answer is discuss stopping screening, not order the test.

Board pearl: Quaternary prevention = the right answer when a vignette describes an elderly patient on 12 medications with adverse drug events — the intervention is medication reconciliation and deprescribing.

Special Populations — Pregnancy, Pediatrics, Underserved

— Folic acid 400–800 mcg daily (4 mg if prior NTD pregnancy or on antiepileptics) starting ≥1 month before conception.

— Update Tdap (each pregnancy, 27–36 wk), influenza, COVID, RSV (32–36 wk Sep–Jan) — maternal immunization protects neonate.

— Avoid live vaccines (MMR, varicella) during pregnancy; give postpartum if nonimmune.

— Screen all pregnancies for HIV, syphilis, HBV, HCV, gonorrhea/chlamydia (if <25 or risk), GBS at 36–37 wk, gestational DM 24–28 wk.

— Newborn screen (state-mandated), hearing, CCHD pulse ox, hep B at birth.

— Lead screening at 12 and 24 months (universal in high-risk areas; risk-based elsewhere).

— Vision screen at well-child visits; objective screen ages 3–5.

— Dental fluoride varnish from primary tooth eruption to 5 years (USPSTF Grade B).

— Autism screen at 18 and 24 months (AAP; USPSTF "I" statement).

— Depression screening annually 12–18; suicide risk assessment.

— HPV vaccine starting 9, routinely 11–12.

— Adolescent confidentiality: STI screening, contraception, mental health typically confidential — varies by state.

— Recognize SDOH screening (food, housing, transportation, IPV) as part of preventive care.

— Refugee health: TB, HBV, parasites, lead, mental health, vaccine catch-up.

— Incarcerated populations: HIV/HCV/STI screening on intake.

Preconception/prenatal primary prevention:

Pediatric prevention schedule highlights:

Underserved populations / health equity:

Key distinction: Universal vs selective vs indicated prevention (Institute of Medicine framework, common in mental health): universal = whole population; selective = subgroup at elevated risk; indicated = individuals with subclinical signs.

Board pearl: Erythromycin eye ointment at birth = primary prevention of gonococcal ophthalmia (mandated in most states); vitamin K IM at birth = primary prevention of hemorrhagic disease — both refusal scenarios test counseling vs reporting.

Complications — When Prevention Fails or Causes Harm

— Overdiagnosis: detecting indolent disease that never would have caused harm (low-risk prostate cancer, DCIS, papillary thyroid microcarcinoma).

— False positives: unnecessary biopsies, anxiety, downstream cost (mammography ~10% recall rate).

— Cascade testing: incidentaloma → CT → biopsy → complication.

— Radiation exposure: cumulative from repeat CTs.

— Anaphylaxis to vaccine components (egg-based flu in severe egg allergy → use cell-based or recombinant).

— Guillain-Barré rare association with influenza vaccine — relative contraindication if GBS within 6 weeks of prior vaccine.

— Intussusception with rotavirus — give first dose by 15 weeks, last by 8 months.

— Live vaccines contraindicated in pregnancy and severe immunocompromise.

— Tamoxifen: VTE, endometrial cancer.

— Aspirin primary prevention: GI/intracranial bleed > cardioprotective benefit in low-risk and elderly.

— Finasteride (BPH/chemoprevention): may increase high-grade prostate cancer detection (controversial).

Harms of overscreening (testing increasingly tested on Step 3):

Lead-time bias: earlier detection appears to prolong survival without actually changing time of death.

Length-time bias: screening preferentially detects slow-growing, indolent cases — inflating apparent survival benefit.

Selection bias / healthy screenee effect: people who get screened are healthier overall.

Vaccine adverse events (rare but tested):

Chemoprevention harms:

Failed tertiary prevention complications: recurrent MI, stroke recurrence, diabetic amputation, ESRD progression — each represents missed secondary prevention opportunity earlier.

Step 3 management: When a vignette describes a 75-year-old man asking for PSA and a 45-year-old asking for whole-body CT, the right answer is counseling about harms of screening, not ordering.

Board pearl: Number needed to screen is often >1000 for cancer screens — the exam expects you to acknowledge that benefit is real but modest at the individual level.

When to Escalate — Referral and Specialist Involvement

— ≥2 1st-degree relatives with breast/ovarian/pancreatic/prostate cancer.

— Breast cancer <50, triple-negative <60, male breast cancer, bilateral disease.

— Ashkenazi Jewish ancestry + any of above.

— Lynch criteria (Amsterdam II, Bethesda): CRC <50, multiple Lynch-associated cancers (endometrial, ovarian, gastric, small bowel, urothelial).

— Suspected FAP (>10 adenomas), hereditary diffuse gastric cancer (CDH1).

— STIs (syphilis, gonorrhea, chlamydia, HIV, HBV, HCV).

— TB (suspected or confirmed).

— Vaccine-preventable diseases (measles, pertussis, meningococcal).

— Foodborne outbreaks.

— Lead poisoning (varies by state, typically ≥3.5 mcg/dL in children per 2021 CDC update).

Genetic counseling referral indications:

Cardiology referral: abnormal stress test, CAC ≥100 in borderline-risk patient, familial hypercholesterolemia (LDL ≥190 untreated), need for PCSK9i.

Endocrinology: secondary osteoporosis workup (premenopausal fracture, Z-score ≤−2.0), uncontrolled DM despite multi-drug therapy.

Hepatology: chronic HCV/HBV requiring DAA/antiviral; cirrhosis surveillance (HCC US q6mo, varices screen).

Mental health: positive PHQ-9 with suicidality, treatment-resistant depression after 2 trials, comorbid SUD requiring MAT.

Public health reporting (mandated):

Inpatient triage in prevention contexts: suicidal ideation with plan, severe alcohol withdrawal risk (CIWA, history of DTs/seizures), TB requiring isolation, child/elder abuse requiring protective placement.

CCS pearl: When you encounter a positive screen on CCS (PHQ-9 with SI, positive TB, mammogram BIRADS 5), immediately order the appropriate consult AND counsel patient — both actions score.

Board pearl: Patient confidentiality yields to mandatory reporting for communicable diseases, child/elder abuse, and Tarasoff (duty to warn identifiable third party) — these supersede HIPAA.

Key Differentials — Distinguishing Prevention Categories

— Primary: intervention before any disease/condition is present. Examples: HPV vaccine, statin in healthy high-risk, smoking cessation in current smoker (preventing future disease), folic acid pre-pregnancy.

— Secondary: intervention in asymptomatic patient to detect or treat early/subclinical disease. Examples: mammography, BP measurement that finds HTN, A1c screen finding prediabetes, Pap finding CIN.

— Secondary = early or asymptomatic disease.

— Tertiary = clinically established disease; goal is reduce complications/recurrence/disability.

— A statin in newly screen-detected hyperlipidemia (no events) = primary prevention of ASCVD (clinical) / secondary in public health framework (treating an asymptomatic abnormality).

— A statin after MI = secondary prevention (clinical) / tertiary (public health).

— Read the stem: if it asks "what level of prevention," use public health. If it says "primary vs secondary prevention of ASCVD," use cardiology.

— Screening = asymptomatic, average or risk-based population.

— Surveillance = known disease, monitoring for progression/recurrence (e.g., colonoscopy q3y after polypectomy, HCC US in cirrhosis).

— Diagnostic = symptomatic, working up a complaint.

Primary vs Secondary — common Step 3 confusion:

Secondary vs Tertiary:

Reconciling the two nomenclatures — Step 3 typically uses public health framework (3 or 4 levels) but cardiology questions use clinical framework (primary = no event yet, secondary = post-event).

Screening vs surveillance vs diagnostic:

Health promotion vs prevention: health promotion targets wellness/quality of life broadly (community fitness programs); prevention specifically targets disease.

Key distinction: A patient with a colonoscopy 3 years after polyp removal is undergoing surveillance, not screening — and the recommendation flows from polyp pathology, not USPSTF age cutoffs.

Board pearl: "Chemoprevention" almost always refers to primary prevention (tamoxifen in high-risk women, aspirin in selected populations historically).

Key Differentials — Confounding Public Health Concepts

— Lead-time bias: screening detects disease earlier; survival from diagnosis looks longer even if death date unchanged.

— Length-time bias: screening preferentially picks up slow-growing disease (longer preclinical phase); fast/aggressive cancers missed between intervals.

— Overdiagnosis bias: detecting disease that would never have become clinically significant (e.g., low-grade prostate cancer in elderly).

— Selection bias: screened populations are systematically different (healthier, better access).

— Correct metric to evaluate screening benefit: disease-specific mortality in RCT, not 5-year survival.

— Good screening test: high sensitivity (don't miss disease), reasonable specificity.

— PPV depends on prevalence — same test has lower PPV in low-prevalence populations → more false positives → harm.

— Confirmatory tests need high specificity to rule in.

— Herd immunity threshold: 1 − 1/R₀; measles ~95%, polio ~80%, COVID variable.

— Cluster vs individual randomization in community trials.

— Ecological fallacy: group-level associations don't necessarily apply to individuals.

— Important health problem; recognizable latent stage; accepted treatment; suitable test; acceptable to population; natural history understood; agreed policy on whom to treat; cost-effective; continuing process.

Bias and study design pitfalls in screening evidence:

Sensitivity, specificity, PPV in screening context:

Public health intervention concepts:

Wilson-Jungner criteria for a worthwhile screening program:

Quaternary prevention (Marc Jamoulle): action to mitigate or avoid harm from medical interventions themselves — increasingly relevant for deprescribing and shared decision-making vignettes.

Key distinction: A 95% sensitive test for a 1/10,000 disease still produces mostly false positives — Bayes' theorem on Step 3 frequently illustrates why we don't screen low-prevalence diseases in average-risk populations.

Board pearl: Bradford Hill criteria (strength, consistency, temporality, biological gradient, plausibility, coherence, experiment, analogy, specificity) inform causality — temporality is the only one that is necessary.

Secondary Prevention / Long-Term Plan by Condition

— Aspirin 81 mg indefinitely; P2Y12 inhibitor 12 months.

— High-intensity statin (atorvastatin 80 or rosuvastatin 40); LDL goal <70, consider <55.

— Beta-blocker ≥3 years (longer if HFrEF).

— ACEi/ARB if EF <40%, HTN, DM, or CKD.

— Aldosterone antagonist if EF ≤40% with HF/DM.

— Cardiac rehab referral within 1–2 weeks.

— Sublingual nitroglycerin PRN.

— Influenza, pneumococcal, COVID vaccines.

— Antiplatelet (ASA 81 or clopidogrel 75); short-term DAPT 21 days then mono for minor stroke/high-risk TIA.

— Anticoagulation if AFib (DOAC preferred).

— High-intensity statin; LDL <70.

— BP <130/80.

— A1c <7%.

— Smoking cessation.

— Carotid revascularization if symptomatic 70–99%.

Post-MI tertiary prevention bundle (mandatory CCS orders):

Post-stroke/TIA:

Post-VTE: anticoagulation 3 months (provoked) vs indefinite (unprovoked, high recurrence); screen for malignancy age-appropriate.

Post-fracture (osteoporosis): bisphosphonate or denosumab; calcium 1200 mg, vitamin D 800–1000 IU; fall prevention; reassess BMD in 2 years.

Diabetes tertiary: A1c individualized (~7%), BP <130/80, statin, ACEi/ARB if albuminuria, SGLT2i if CKD/HF/ASCVD, GLP-1RA if ASCVD/obesity, annual eye/foot/microalbumin, pneumococcal/influenza/Hep B/zoster vaccines.

COPD tertiary: bronchodilator escalation, pulmonary rehab if mMRC ≥2, smoking cessation, oxygen if SpO2 ≤88%, vaccinations.

Step 3 management: Discharge order sets should default to the full bundle — partial answers (e.g., aspirin + statin only post-MI) are wrong because beta-blocker and ACEi are missing.

Board pearl: Cardiac rehab reduces all-cause mortality ~20% post-MI yet is referred only ~30% of the time — Step 3 frequently tests "what is most underutilized."

Follow-Up, Monitoring, Rehab and Counseling

— HTN: 1 month after med initiation/titration, then q3–6mo when stable.

— DM: A1c q3mo if not at goal, q6mo when stable; annual eye, foot, microalbumin, lipids.

— Hyperlipidemia: lipid panel 4–12 wk after statin start, then 3–12mo.

— Osteoporosis: DEXA q2y on therapy.

— Post-MI: 1–2 weeks, then 3 months, then q6mo.

— Post-bariatric: nutrition labs q3–6mo then annually; B12, folate, iron, vitamin D, Ca, PTH.

— 5 A's (tobacco, alcohol, diet): Ask, Advise, Assess readiness, Assist (resources/Rx), Arrange follow-up.

— Motivational interviewing: OARS (Open questions, Affirmations, Reflections, Summaries); roll with resistance, explore ambivalence.

— Stages of change (Prochaska): precontemplation → contemplation → preparation → action → maintenance; intervention matched to stage.

— Cardiac rehab post-MI/CABG/PCI/HF/valve surgery: 36 sessions over 12 weeks.

— Pulmonary rehab in COPD with mMRC ≥2, recent exacerbation.

— Stroke rehab: PT/OT/SLP starting in hospital, continuing outpatient.

— Home BP cuffs (validated), at least 2 readings AM/PM for 7 days for diagnosis confirmation.

— Glucose monitoring frequency tailored to insulin regimen.

— Peak flow or symptom diary for asthma.

Standard follow-up cadence for chronic preventive care:

Behavioral counseling structure:

Rehab programs:

Vaccine documentation and reminders: EHR-based reminders, patient portal, registry submission — system-level prevention.

Patient self-monitoring:

Step 3 management: A patient on statin returning at 6 weeks with LFT 1.5× ULN and no symptoms → continue statin; only stop if >3× ULN or symptomatic hepatitis. Don't reflexively discontinue.

Board pearl: USPSTF gives Grade A to behavioral counseling for healthy diet + activity in adults with CV risk factors — Step 3 expects you to order this, not just mention it.

Ethical, Legal, and Patient Safety Considerations

— Patient must understand the purpose, benefits, harms (false positives, overdiagnosis), alternatives, and consequences of declining.

— Particularly important for PSA, low-dose CT lung screening, genetic testing — shared decision-making is mandated.

— Documenting "patient declines after discussion of risks/benefits" is appropriate when patient refuses recommended screening.

— Suspected child abuse/neglect (all 50 states, professional reporters).

— Elder abuse (most states).

— Intimate partner violence: counseling and resources required; reporting varies by state — most do not mandate reporting of competent adults unless weapon-inflicted injury.

— Reportable communicable diseases.

— Impaired drivers (varies by state, e.g., CA mandates reporting dementia/lapse of consciousness).

— Pre- and post-test counseling required.

— GINA (Genetic Information Nondiscrimination Act) prohibits employment and health insurance discrimination but not life, disability, or long-term care insurance.

— Duty to warn family members? Generally patient-mediated; clinician encourages but cannot disclose without consent (with rare Tarasoff-like exceptions).

— Respect parental refusal after thorough counseling unless child abuse/neglect threshold met.

— Document discussion; offer revisit; consider AAP Refusal to Vaccinate form.

— Public health override (school mandates, outbreak quarantine) is legal but ethically constrained.

— Hospital discharge without medication reconciliation → adverse drug event.

— Missing follow-up appointment scheduling within 7 days post-MI/CHF → readmission risk.

— Teach-back method at discharge reduces error and readmissions.

Informed consent in screening:

Mandatory reporting (overrides confidentiality):

Genetic testing ethics:

Vaccine refusal:

Transition-of-care prevention failures (Step 3 favorite):

Resource allocation/equity: offering screening only to insured patients = ethical violation; safety-net referral required.

Step 3 management: When a vignette describes a patient discharged on 11 medications who returns confused, the right next step is medication reconciliation and deprescribing — quaternary prevention.

Board pearl: Confidentiality with adolescents for STI, contraception, mental health is protected in most states — but report if abuse or imminent self-harm.

High-Yield Associations and Rapid-Fire Facts

— A = recommend (high certainty, substantial benefit) — do it.

— B = recommend (moderate certainty/benefit) — do it.

— C = selective offer based on individual judgment.

— D = recommend against.

— I = insufficient evidence.

— Mammography starts at 40 (USPSTF 2024).

— Colorectal screening starts at 45 (2021).

— Aspirin primary prevention not recommended ≥60 (2022).

— HBV screen all adults at least once (2023).

— Anxiety screen adults <65 (Grade B, 2023).

— Lung CT criteria broadened to 50–80, 20 pack-years (2021).

— Bike helmet → primary.

— Newborn metabolic screen → secondary.

— Insulin in T1DM → tertiary.

— Salt fortification with iodine → primordial.

— DAPT post-stent → tertiary.

— Cervical cancer vaccine → primary.

— Pap smear → secondary.

— Hysterectomy for stage I cervical cancer → tertiary.

USPSTF grade quick reference:

Grade D classics (do NOT screen): ovarian cancer in average risk, pancreatic cancer in average risk, testicular cancer, asymptomatic carotid stenosis, PSA ≥70, vitamin D for fall prevention community-dwellers, beta-carotene/vitamin E for CVD/cancer, hormone therapy for chronic disease prevention in postmenopausal women.

Recent updates to know:

Prevention-level mappings (rapid fire):

Largest impact interventions (population-level): clean water, sanitation, vaccination, tobacco control, motor vehicle safety, family planning, food fortification, occupational safety — CDC's "10 great public health achievements."

NNT highlights: statin primary prevention ~100 over 5 years; smoking cessation ~5–10 for major morbidity over decades; mammography ~1000 to prevent one breast cancer death over 10 years.

Step 3 management: When you see "most cost-effective" in a stem — answer is almost always vaccination or smoking cessation counseling.

Board pearl: Tobacco cessation is the single most important modifiable risk factor across nearly every chronic disease — it is the default correct counseling answer when smoking is in the history.

Board Question Stem Patterns

— Stem: "A 50-year-old man receives the shingles vaccine. This is an example of what level of prevention?"

— Answer: Primary (no disease, preventing onset).

— Trap: confusing with "secondary" because patient is at risk — risk factors alone don't make it secondary.

— Stem: "A 65-year-old male former smoker (30 pack-years, quit 5 years ago) establishes care. Which is most appropriate?"

— Answer: One-time AAA ultrasound + low-dose CT lung screen + pneumococcal vaccine + colorectal screen.

— Trap: ordering carotid US (Grade D) or PSA without shared decision.

— Stem: "A new screening test detects cancer 2 years earlier; 5-year survival improves but mortality unchanged."

— Answer: Lead-time bias.

— Stem: "65yo man discharged after STEMI; which medication is most likely to reduce all-cause mortality?"

— Answer: depends on choices — high-intensity statin, beta-blocker, ACEi, aspirin all qualify; cardiac rehab if listed often wins for "most underutilized but evidence-based."

— Stem: "Parents refuse HPV vaccine for 12-year-old daughter."

— Answer: Provide education, address concerns, revisit at next visit — do not coerce, do not report.

— Stem: "82-year-old woman with severe dementia, life expectancy <5 years, asks about mammogram."

— Answer: Discuss stopping screening — benefit no longer outweighs harm.

— Stem: Elderly patient on 14 meds with falls and confusion.

— Answer: Medication reconciliation and deprescribing Beers-criteria offenders (anticholinergics, benzos, sliding-scale insulin).

— Stem: 4-year-old with patterned bruises and inconsistent history.

— Answer: Report to CPS, do not require parental consent or proof.

Pattern 1 — Classification question:

Pattern 2 — Best next step in well visit:

Pattern 3 — Bias identification:

Pattern 4 — Post-event management:

Pattern 5 — Ethics/refusal:

Pattern 6 — Stop screening:

Pattern 7 — Deprescribing/quaternary:

Pattern 8 — Mandatory reporting:

Board pearl: When stem highlights shared decision-making, expect Grade C screening (PSA 55–69, low-dose aspirin 40–59) as the right answer modality.

One-Line Recap

Prevention is the act of matching the right intervention to the right disease stage: primary stops disease before it starts, secondary catches it before it speaks, and tertiary blunts its damage once established — and on Step 3, the right answer is the one that fits the patient's current position on that spectrum, supported by USPSTF Grade A/B evidence and shared decision-making.

— Primordial removes the risk factor itself (policy, environment); primary prevents disease in at-risk individuals (vaccines, statins for high ASCVD risk, behavioral counseling); secondary detects asymptomatic/early disease (USPSTF screening grid); tertiary prevents complications/recurrence in established disease (post-MI bundle, DM foot care, cardiac rehab); quaternary prevents iatrogenic harm (deprescribing, stop screening when life expectancy short).

— USPSTF grades A and B = do; D = do not; C = shared decision; I = insufficient evidence. Memorize age cutoffs: mammography 40–74, CRC 45–75, lung CT 50–80 + 20 pack-years, AAA one-time men 65–75 ever-smokers.

— Tertiary bundles (post-MI, post-stroke, post-fracture, post-VTE, DM) are CCS gold — order the full bundle (antiplatelet + statin + BP control + lifestyle + rehab + vaccines), not partial therapy.

— Ethics/safety hooks: informed consent for screening with harms; mandatory reporting (abuse, communicable disease, Tarasoff); GINA protects health/employment but not life insurance; medication reconciliation at every transition of care; respect vaccine refusal after counseling but report true neglect; stop screening when life expectancy <10 years; deprescribe in frail elderly — quaternary prevention is now squarely on the exam.

Rapid recap bullets:

One-line action rule: Identify the patient's disease state first, then choose the evidence-graded intervention that prevents the next adverse outcome — the prevention level follows automatically.